Printer Friendly

DEPRENYL RESEARCH NOTES NO CHANGE IN COMPANY TO ACCOUNT FOR CURRENT PRESSURES ON SHARE PRICE

 DEPRENYL RESEARCH NOTES NO CHANGE IN COMPANY TO ACCOUNT
 FOR CURRENT PRESSURES ON SHARE PRICE
 TORONTO, May 21 /PRNewswire/ -- Deprenyl Research Limited (TSE: DEP; NASDAQ: DEPLF) has examined the basis of the current pressures on the company's share price. There is nothing within the company's business progress, profitability, existing drugs, drug pipeline, or anything else that has changed and the company fully expects to increase it's pharmaceutical revenues and earnings this year.
 The company said its best assessment is that a number of large funds have decided to liquidate their holdings in several bio and pharmaceutical stocks including Deprenyl's. A group of brokers has bought the last 514,000 shares offered for sale by one of these funds.
 Deprenyl Research Limited is an independent Canadian pharmaceutical company which is building a pipeline of products largely devoted to Parkinson's disease, other neurological diseases and disorders of aging.
 -0- 5/21/92
 /CONTACT: Martin Barkin, president, or James P. Doherty, vice chairman, of Deprenyl, 416-537-4372, or Irving L. Straus, of Straus Corporate Communications, 212-768-2477, for Deprenyl/
 (DEPLF) CO: Deprenyl Research Limited ST: Ontario IN: MTC SU:


KD-OS -- NY067 -- 2861 05/21/92 12:54 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 21, 1992
Words:193
Previous Article:'APPROVABLE' LETTER RECEIVED BY SEARLE/LOREX FOR AMBIEN
Next Article:PENN TRAFFIC RECORDS 14.0 PERCENT INCREASE IN OPERATING INCOME
Topics:


Related Articles
DEPRENYL RESEARCH COMMENTS ON STOCK PRICE
DEPRENYL RESEARCH CHAIRMAN ISSUES STATEMENT ON SELL ADVISORY
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL USA ANNOUNCES CONDITIONAL LISTING ON TORONTO STOCK EXCHANGE
DEPRENYL RESEARCH ANNOUNCES FINAL PROSPECTUS OF BONE HEALTH INC.
DEPRENYL USA ANNOUNCES NO CHANGE AT COMPANY TO ACCOUNT FOR SHARE PRICE PRESSURE
DEPRENYL RESEARCH LTD. & BONE HEALTH INC. TO AWAIT FULL ANALYSIS OF CLINICAL TRIALS BEFORE ISSUING FINAL AMENDMENTS TO PROSPECTUS
DEPRENYL USA CLASS A WARRANTS MAYBE EXERCISED UNTIL APRIL 19, 1993
DEPRENYL RESEARCH REPORTS EARNINGS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters